Molecular targeted therapies such as palbociclib, a first-in-class potent oral inhibitor of cyclin-dependent kinases 4 and 6, have demonstrated improved progression-free survival compared with endocrine therapy alone in postmenopausal patients with HR+, HER2-recurrent or stage IV breast cancer [3,4]. The gene discussed is ERBB2; the disease is breast cancer.